NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
14.29
+0.06 (0.42%)
Jul 15, 2026, 12:57 PM EDT - Market open
NeoGenomics Revenue
NeoGenomics had revenue of $186.67M in the quarter ending March 31, 2026, with 11.09% growth. This brings the company's revenue in the last twelve months to $745.97M, up 10.95% year-over-year. In the year 2025, NeoGenomics had annual revenue of $727.33M with 10.11% growth.
Revenue (ttm)
$745.97M
Revenue Growth
+10.95%
P/S Ratio
2.53
Revenue / Employee
$298,388
Employees
2,500
Market Cap
1.86B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 727.33M | 66.77M | 10.11% |
| Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
| Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
| Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
| Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
| Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
| Dec 31, 2019 | 408.83M | 132.09M | 47.73% |
| Dec 31, 2018 | 276.74M | 36.49M | 15.19% |
| Dec 31, 2017 | 240.25M | 8.44M | 3.64% |
| Dec 31, 2016 | 231.81M | 132.01M | 132.27% |
| Dec 31, 2015 | 99.80M | 12.73M | 14.62% |
| Dec 31, 2014 | 87.07M | 20.60M | 31.00% |
| Dec 31, 2013 | 66.47M | 6.60M | 11.02% |
| Dec 31, 2012 | 59.87M | 16.38M | 37.68% |
| Dec 31, 2011 | 43.48M | 9.11M | 26.51% |
| Dec 31, 2010 | 34.37M | 4.90M | 16.63% |
| Dec 31, 2009 | 29.47M | 9.45M | 47.23% |
| Dec 31, 2008 | 20.02M | 8.51M | 73.97% |
| Dec 31, 2007 | 11.50M | 5.03M | 77.65% |
| Dec 31, 2006 | 6.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.14B |
| Sotera Health Company | 1.19B |
| OPKO Health | 581.12M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
| Castle Biosciences | 339.92M |
NEO News
- 4 hours ago - NeoGenomics price target raised to $19 from $14 at TD Cowen - TheFly
- 2 days ago - NeoGenomics price target raised to $16 from $11 at BofA - TheFly
- 6 days ago - NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic - TheFly
- 6 days ago - NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer - Business Wire
- 8 days ago - NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026 - Business Wire
- 20 days ago - NeoGenomics appoints Starrett to its Board of Directors - TheFly
- 20 days ago - NeoGenomics Appoints Carolyn Starrett to its Board of Directors - Business Wire
- 4 weeks ago - NeoGenomics announces pricing of $275M convertible senior notes offering - TheFly